ineligible is a policy decision set by the employer (what the program allows)
I think a lot of companies were going to see maybe shifting away from this custom approach because they are afraid that the FDA could come in any day and shut them down and say you cant do this anymore. George Ball, Indiana University associate professor of operations and decision technologies, has a different take on the situation
Personalized care is key to real, lasting results
To overcome this limitation, scientists have developed GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide, tilpotide, etc., which extend the half-life to the weekly formulation level through structural modification, achieving sustained regulation
Wegovy scripts were essentially flat quarter-to-quarter, even as supply was raised